Hepatology

A long-term study shows that recurrence beyond the Milan criteria, rather than recurrence itself, drives poorer survival after curative hepatocellular carcinoma resection.

Study shows DAAs and interferon offer similar long-term protection against hepatocellular carcinoma after hepatitis C cure and introduces a nomogram to predict 8-year HCC risk.

Phase II ELMWOOD trial shows elafibranor is well tolerated and improves liver biochemistry and pruritus in primary sclerosing cholangitis, supporting further trials.

A phase 2 trial finds tinengotinib demonstrates anti-tumour activity in previously treated advanced cholangiocarcinoma with FGFR alterations.

A new multinational study reports that rifaximin use in cirrhosis and hepatic encephalopathy is linked to significantly higher risks of antimicrobial resistance and severe infections.

Large PBC cohort shows current liver stiffness measurement >10 kPa predicts hepatic decompensation, outperforming biochemical response or LSM trajectory.

New research confirms the GOLDEN model reliably predicts HBsAg loss in interferon-treated chronic hepatitis B patients, supporting more personalized treatment strategies.

Bioinformatics work identifies FAM72A–D as powerful prognostic markers in liver cancer and unveils a compact FAM72 risk score that outperforms existing gene models.